These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 21849540

  • 21. Cholecystokinin 1 receptor activation restores normal mTORC1 signaling and is protective to Purkinje cells of SCA mice.
    Wozniak EAL, Chen Z, Paul S, Yang P, Figueroa KP, Friedrich J, Tschumperlin T, Berken M, Ingram M, Henzler C, Pulst SM, Orr HT.
    Cell Rep; 2021 Oct 12; 37(2):109831. PubMed ID: 34644575
    [Abstract] [Full Text] [Related]

  • 22. Experimental Treatment with Edaravone in a Mouse Model of Spinocerebellar Ataxia 1.
    Sucha M, Benediktova S, Tichanek F, Jedlicka J, Kapl S, Jelinkova D, Purkartova Z, Tuma J, Kuncova J, Cendelin J.
    Int J Mol Sci; 2023 Jun 26; 24(13):. PubMed ID: 37445867
    [Abstract] [Full Text] [Related]

  • 23. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice.
    Zu T, Duvick LA, Kaytor MD, Berlinger MS, Zoghbi HY, Clark HB, Orr HT.
    J Neurosci; 2004 Oct 06; 24(40):8853-61. PubMed ID: 15470152
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1.
    Oz G, Nelson CD, Koski DM, Henry PG, Marjanska M, Deelchand DK, Shanley R, Eberly LE, Orr HT, Clark HB.
    J Neurosci; 2010 Mar 10; 30(10):3831-8. PubMed ID: 20220018
    [Abstract] [Full Text] [Related]

  • 26. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2.
    Liu J, Tang TS, Tu H, Nelson O, Herndon E, Huynh DP, Pulst SM, Bezprozvanny I.
    J Neurosci; 2009 Jul 22; 29(29):9148-62. PubMed ID: 19625506
    [Abstract] [Full Text] [Related]

  • 27. Loss of beta-III spectrin leads to Purkinje cell dysfunction recapitulating the behavior and neuropathology of spinocerebellar ataxia type 5 in humans.
    Perkins EM, Clarkson YL, Sabatier N, Longhurst DM, Millward CP, Jack J, Toraiwa J, Watanabe M, Rothstein JD, Lyndon AR, Wyllie DJ, Dutia MB, Jackson M.
    J Neurosci; 2010 Apr 07; 30(14):4857-67. PubMed ID: 20371805
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Astroglia contribute to the pathogenesis of spinocerebellar ataxia Type 1 (SCA1) in a biphasic, stage-of-disease specific manner.
    Kim JH, Lukowicz A, Qu W, Johnson A, Cvetanovic M.
    Glia; 2018 Sep 07; 66(9):1972-1987. PubMed ID: 30043530
    [Abstract] [Full Text] [Related]

  • 31. Discovery of Novel Activators of Large-Conductance Calcium-Activated Potassium Channels for the Treatment of Cerebellar Ataxia.
    Srinivasan SR, Huang H, Chang WC, Nasburg JA, Nguyen HM, Strassmaier T, Wulff H, Shakkottai VG.
    Mol Pharmacol; 2022 Jul 07; 102(1):438-449. PubMed ID: 35489717
    [Abstract] [Full Text] [Related]

  • 32. Early molecular layer interneuron hyperactivity triggers Purkinje neuron degeneration in SCA1.
    Pilotto F, Douthwaite C, Diab R, Ye X, Al Qassab Z, Tietje C, Mounassir M, Odriozola A, Thapa A, Buijsen RAM, Lagache S, Uldry AC, Heller M, Müller S, van Roon-Mom WMC, Zuber B, Liebscher S, Saxena S.
    Neuron; 2023 Aug 16; 111(16):2523-2543.e10. PubMed ID: 37321222
    [Abstract] [Full Text] [Related]

  • 33. Therapeutic potential of d-cysteine against in vitro and in vivo models of spinocerebellar ataxia.
    Ohta T, Morikawa Y, Sato M, Konno A, Hirai H, Kurauchi Y, Hisatsune A, Katsuki H, Seki T.
    Exp Neurol; 2021 Sep 16; 343():113791. PubMed ID: 34157318
    [Abstract] [Full Text] [Related]

  • 34. In vivo analysis of cerebellar Purkinje cell activity in SCA2 transgenic mouse model.
    Egorova PA, Zakharova OA, Vlasova OL, Bezprozvanny IB.
    J Neurophysiol; 2016 Jun 01; 115(6):2840-51. PubMed ID: 26984424
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Targeting mGlu1 Receptors in the Treatment of Motor and Cognitive Dysfunctions in Mice Modeling Type 1 Spinocerebellar Ataxia.
    Liberatore F, Antenucci N, Tortolani D, Mascio G, Fanti F, Sergi M, Battaglia G, Bruno V, Nicoletti F, Maccarrone M, Notartomaso S.
    Cells; 2022 Dec 03; 11(23):. PubMed ID: 36497172
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.